Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23018IDB-L5

Select Item

Empower your strategies with our Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 report and make more profitable business decisions.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol.

The Chronic Kidney Disease (Chronic Renal Failure) drugs in development market research report provide comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Chronic Kidney Disease (Chronic Renal Failure)
Key Targets
· Cytochrome P450 11B2 Mitochondrial; Apolipoprotein L1 ; Endothelin 1 Receptor; Solute Carrier Family 22 Member 12; Mineralocorticoid Receptor; Kelch Like ECH Associated Protein 1; Interleukin 6; Glucagon Like Peptide 1 Receptor; Coagulation Factor XI; and Soluble Guanylate Cyclase
Key Mechanisms of Action
· Cytochrome P450 11B2 Mitochondrial Inhibitor; Endothelin 1 Receptor Antagonist; Apolipoprotein L1 Inhibitor; Solute Carrier Family 22 Member 12 Inhibitor; Interleukin 6 Inhibitor; Mineralocorticoid Receptor Antagonist; Kelch Like ECH Associated Protein 1 Inhibitor; Glucagon Like Peptide 1 Receptor Agonist; Coagulation Factor XI Inhibitor; and Soluble Guanylate Cyclase Activator
Key Routes of Administration
· Oral; Intravenous; Subcutaneous; Parenteral; Topical; Intraarticular; Inhalational; Intramuscular; Intralesional; and Intravenous Bolus
Key Molecule Types
· Small Molecule; Cell Therapy; Monoclonal Antibody; Biologic; Synthetic Peptide; Peptide; Antisense Oligonucleotide; Fusion Protein; Gene Therapy; and Recombinant Protein
Major Companies
· AstraZeneca Plc; MD Healthcare Inc; Maze Therapeutics Inc; Novo Nordisk AS; Bayer AG; Algernon Pharmaceuticals Inc; Elicio Therapeutics Inc; Chinook Therapeutics Inc; Boehringer Ingelheim International GmbH; and Scohia Pharma Inc

Scope

  • Therapeutics in Development: Covering 170 molecules, with 164 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Chronic Kidney Disease (Chronic Renal Failure) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Chronic Kidney Disease (Chronic Renal Failure) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chronic Kidney Disease (Chronic Renal Failure) treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Acahealth Pharma and Biotech Co Ltd
AdAlta Ltd
Aileron Therapeutics Inc
Alexion Pharmaceuticals Inc
Algernon Pharmaceuticals Inc
Algomedix Inc
Alpha Young LLC
Anagenics Ltd
Angiotensin Therapeutics Inc
Aplagon Oy
Arbormed Co Ltd
Arch Biopartners Inc
Aria Pharmaceuticals Inc
Aronora Inc
Arthrosi Therapeutics Inc
Asahi Kasei Pharma Corp
AstraZeneca Plc
Bayer AG
BerGenBio ASA
Boehringer Ingelheim International GmbH
Byomass Inc
CAMP Therapeutics Inc
Cascade Pharmaceuticals Inc
Ceptur Therapeutics Inc
Certa Therapeutics Pty Ltd
Chinook Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp.
CinCor Pharma Inc
Cinkate Corp
Coegin Pharma AB
CrystalGenomics Inc
CSL Ltd
Daiichi Sankyo Co Ltd
DiaMedica Therapeutics Inc
Dimerix Ltd
DJS Antibodies Ltd
Drug Farm Inc
DURECT Corp
Eagle Pharmaceuticals Inc
EHL Bio Co Ltd
Eli Lilly and Co
Elicio Therapeutics Inc
Ennovabio
Enyo Pharma SA
Evgen Pharma Plc
Evotec SE
Fortress Biotech Inc
Function Therapeutics Inc
Future Medicine Co Ltd
G&P Bioscience Co Ltd
G3 Pharmaceuticals Inc
Galderma SA
Gila Therapeutics Inc
Gmax Biopharm LLC
GNI Group Ltd
Goldilocks Therapeutics Inc
Gubra ApS
Haisco Pharmaceutical Group Co Ltd
Hangzhou Metai Pharmaceutical Technology Co Ltd
Helixmith Co Ltd
Hinova Pharmaceuticals Co Ltd
Hybridize Pharma BV
Icagen Inc
iCELL Biotechnology Co Ltd
Inozyme Pharma Inc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Jikei University School of Medicine
Johnson & Johnson
KBP Biosciences Co Ltd
Keio University
Kibow Biotech Inc
KidneyCure Ltd
Klotho Therapeutics Inc
Leflore Technologies LLC
MabTics
Maze Therapeutics Inc
MD Healthcare Inc
MedAbome Inc
MedBiome Inc
Meridigen Biotech Co Ltd
Mineralys Therapeutics Inc
Mission Therapeutics Ltd
Novartis AG
NovMetaPharma Co Ltd
Novo Nordisk AS
OccuRx Pty Ltd
Oisin Biotechnologies
Oneness Biotech Co Ltd
Opsidio LLC
Orgenesis Inc
OrthoTrophix Inc
Osaka University Hospital
Pharmaxis Ltd
Pharmicell Co Ltd
Poxel SA
Prokidney Corp
Purespring Therapeutics Ltd
RAGE Biotech Pty Ltd
Reata Pharmaceuticals Inc
Redx Pharma Plc
Rege Nephro Co Ltd
Reliance Life Sciences Pvt Ltd
Renibus Therapeutics Inc
Resverlogix Corp
Revelation Biosciences Inc
Saniona AB
Sarfez Pharmaceuticals Inc
Scohia Pharma Inc
Senolytic Therapeutics Inc
Sentien Biotechnologies Inc
Shanghai Pharmaceutical Group Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
siRNAgen Therapeutics Corp
Skye Bioscience Inc
Suzhou Regend Therapeutics Co Ltd
TagCyx Biotechnologies
Two Cells Co Ltd
Unicocell Biomed Co Ltd
Unicycive Therapeutics Inc
Unicyte AG
University of Queensland
Vall d’Hebron Institute of Research
Vascular BioSciences
VCANBIO Cell and Gene Engineering Corp Ltd
Ventus Therapeutics Inc
Vertex Pharmaceuticals Inc
VESSL Therapeutics Ltd
Vidasym Inc
Vivazome Therapeutics Pty Ltd
Vivoryon Therapeutics NV
Walden Biosciences Inc
Wuxi Biocity Biopharma Co Ltd
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Chronic Kidney Disease (Chronic Renal Failure) reports
Pharmaceuticals
New
Pharma M&A Deals H1 2026 - Top Themes: Strategic Intelligence
$495 | July 2026
Pharmaceuticals
New
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment,…
$17,995 | July 2026
Pharmaceuticals
New
Melanoma: Epidemiology Forecast to 2035
$9,995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 in real time.

  • Access a live Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more